Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials